Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) has shared an announcement.
Shanghai Bio-Heart Biological Technology reported its first full year of revenue, booking RMB44.9 million in 2025 from the global launch of its Iberis RDN system for resistant hypertension, including the first commercial procedure in Europe and progress on a SAKURA-SCB ischemic heart disease trial in Japan. Despite a narrowed net loss of RMB68.4 million and reduced loss per share, the company’s higher R&D spending and sharply lower cash balance highlight its continued investment-led growth strategy and the financial pressure of scaling commercialization in the competitive cardiovascular device market.
The most recent analyst rating on (HK:2185) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Shanghai Bio-Heart Biological Technology Co., Ltd. Class H stock, see the HK:2185 Stock Forecast page.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-Heart Biological Technology Co., Ltd. is a PRC-based medical technology company focused on innovative cardiovascular devices. Its primary products include the Iberis RDN system for treating resistant hypertension and hypertension in patients intolerant to drugs, with a growing international market focus including Europe and Japan.
Average Trading Volume: 324,545
Technical Sentiment Signal: Sell
Current Market Cap: HK$949.3M
See more insights into 2185 stock on TipRanks’ Stock Analysis page.